Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(a) Effective as of July17, 2012, Stephen Ross resigned from his position as the Chief Financial Officer and Director of Remedent, Inc., a Nevada corporation (the "Company").

(b) Effective upon Mr. Ross's resignation, the Board of Directors re-appointed Mr. Philippe Van Acker, a current Director of the Company, to replace Mr. Ross as Chief Financial Officer of the Company. Mr. Van Acker held already the position of Chief Financial Officer as of March 30, 2005. Effective December 18, 2008, Mr. Van Acker resigned as Chief Financial Officer and became our Chief Accounting Officer as well as assuming a position on the Board of Directors. From July 2001 to March 30, 2005, Mr. Van Acker has served as a director of our subsidiary, Remedent N.V. where he has also served as financial controller. From 1999 to 2001, Mr. Van Acker served as Director of Finance for DMDS, Ltd., a European subsidiary of Dental & Medical Diagnostic Systems, Inc., a company that developed and marketed high-tech dental equipment. From 1992 to 1999, Mr. Van Acker held various positions with Pfizer Medical Technology Group. Mr. Van Acker resides in Belgium.

There have been no material changes to any agreements or arrangements between Mr. Van Acker and the Company or its subsidiaries as a result of his appointment to Chief Financial Officer.